` ENZY (Enzymatica AB (publ)) vs OMX Stockholm 30 Comparison - Alpha Spread

ENZY
vs
OMX Stockholm 30

Over the past 12 months, ENZY has outperformed OMX Stockholm 30, delivering a return of -4% compared to the OMX Stockholm 30's 9% drop.

Stocks Performance
ENZY vs OMX Stockholm 30

Loading

Performance Gap
ENZY vs OMX Stockholm 30

Loading
ENZY
OMX Stockholm 30
Difference

Performance By Year
ENZY vs OMX Stockholm 30

Loading
ENZY
OMX Stockholm 30
Add Stock

Competitors Performance
Enzymatica AB (publ) vs Peers

OMX Stockholm 30
ENZY
LLY
JNJ
NOVO B
ROG
Add Stock

Enzymatica AB (publ)
Glance View

Market Cap
864.1m SEK
Industry
Pharmaceuticals

Enzymatica AB engages in the research, development, and sale of medical technology products. The company is headquartered in Lund, Skane and currently employs 26 full-time employees. The company went IPO on 2011-06-14. The company researches, develops and registers enzyme-based health and wellbeing products. The firm uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The firm conducts clinical studies of ColdZyme Munspray, a cold medicine. The company operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.

ENZY Intrinsic Value
1.87 SEK
Overvaluation 47%
Intrinsic Value
Price
E
Back to Top